10-K: Coya Therapeutics Reports 2024 Financial Results, Highlights Pipeline Expansion

Coya Therapeutics, a clinical-stage biotechnology company, announces its 10-K filing, highlighting pipeline expansion and financial results for the year ended December 31, 2024.

Summary

• Coya Therapeutics, a clinical-stage biotechnology company, reported a net loss of $14.9 million for the year ended December 31, 2024, and an accumulated deficit of $40.7 million.
• The company is focused on developing therapies to enhance regulatory T cell (Treg) function for neurodegenerative, autoimmune, and metabolic diseases.
• Coya's lead asset, COYA 302, is a Treg-enhancing biologic currently in IND-enabling studies for ALS, with plans to file an IND in the second quarter of 2025.
• The company is expanding its pipeline to include FTD, PD, and AD, with COYA 302 and COYA 303 as key assets.
• Coya is leveraging in-licensed technology to advance its Treg exosome therapies (COYA 206) and actively pursuing partnering opportunities for COYA 301 and COYA 302.
• The company's strategy includes advancing COYA 302, establishing COYA 301 as a backbone for combination therapies, and selectively entering new discovery relationships.
• Coya is developing COYA 303, a biologic combination of COYA 301 and a GLP-1 RA, for the treatment of inflammatory diseases, with preclinical study results expected to be published in the first half of 2025.
• The company is also developing COYA 206, a next-generation Treg-derived exosome product candidate, utilizing technology in-licensed from Carnegie Mellon University.
• Coya anticipates filing an IND for COYA 302 in ALS in the second quarter of 2025 and potentially filing an IND for COYA 302 in FTD before the end of 2025.
• The company believes its Treg-modifying potential therapeutic modalities can advance the standard of care for neurodegenerative and autoimmune diseases.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's progress in pipeline expansion and strategic collaborations, the increased net loss and the need for additional capital raise concerns. The delay in the COYA 302 trial due to FDA requirements further tempers the outlook.

Positives

• Coya is expanding its pipeline to include FTD, PD, and AD, indicating growth and potential for broader application of its technology.
• The company is leveraging in-licensed technology from Carnegie Mellon University to develop COYA 206, a next-generation Treg-derived exosome product candidate.
• Coya received an up-front, nonrefundable payment of $7.5 million in January 2024 from Dr. Reddy's Laboratories as part of the DRL Development Agreement.
• The DRL Development Agreement also includes up to $40.0 million in development milestones and up to $677.3 million in sales milestones related to the New Territories.
• Coya will be owed royalties by Dr. Reddy's on Net Sales of COYA 302 in the low to mid-teens.
• The company's cash and cash equivalents of $38.3 million as of December 31, 2024, are expected to fund operating expenses and capital expenditure requirements for at least one year.

Negatives

• Coya reported a net loss of $14.9 million for the year ended December 31, 2024, compared to a net loss of $8.0 million in 2023, indicating increased losses.
• The company's accumulated deficit as of December 31, 2024, was $40.7 million.
• The company will need to raise substantial additional capital to support its continuing operations and pursue its growth strategy.
• The company received an email notification from the FDA stating that additional nonclinical data was required prior to the initiation of the Phase 2 study of COYA 302 in ALS.

Risks

• The company's ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of its current or future product candidates.
• There are no assurances that the company will be successful in obtaining an adequate level of financing as and when needed to finance its operations on terms acceptable to it or at all.
• Any failure to raise capital as and when needed could have a negative impact on the company's financial condition and on its ability to pursue its business plans and strategies.
• The company may encounter substantial delays in its planned clinical trials, or may not be able to conduct or complete its clinical trials on the timelines it expects, if at all.
• The company's dependence on third parties to manufacture its product candidates may increase the risk that preclinical development, clinical development and potential commercialization of its product candidates could be delayed, prevented or impaired.
• The company may not obtain approval for its products and any product for which it obtains required regulatory marketing authorization could be subject to post-approval regulation, and the company may be subject to penalties if it fails to comply with such post-approval requirements.
• The company faces competition from companies that have greater resources than it does, and it may not be able to effectively compete against these companies.
• If others claim the company is infringing on the intellectual property rights of third parties, it may be subject to costly and time-consuming litigation.

Future Outlook

Coya expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its product candidates through all stages of development and clinical trials and, ultimately, seeks regulatory approval.

Management Comments

• The clinical data from these initial studies has served as an important confirmation of the underlying immunomodulatory properties of Tregs and their potential therapeutic benefits.
• We believe our findings have also established mechanistic benefits of combination biologics to address Treg dysfunction as well as highlighted important advantages of scalability and cost.
• We believe COYA 302 is the most clinically advanced of what we hope will be a family of combination therapies that all feature our LD IL-2.
• Given the growing list of indications for which we are developing it, we can now refer to COYA 302 as a Pipeline in a Product.

Industry Context

The document highlights the competitive landscape in Treg-enhancing biologics and Treg-based cellular therapeutics, noting companies like Amgen, Nektar Therapeutics, Abata Therapeutics, and Sonoma Biotherapeutics. It also mentions cell-derived exosome competitors like Evox Therapeutics and Capricor Therapeutics.

Comparison to Industry Standards

• The document mentions several competitor companies developing Biologic approaches to enhancing Tregs, leveraging IL-2 formulations, including Amgen (AMGN), Nektar Therapeutics (NKTR), Merck (MRK), Xencor (XNCR), Cue Biopharma (CUE), Moderna (MRNA), and ILTOO Pharma.
• Competitor companies developing Treg based cellular therapeutics include: Abata Therapeutics, Sonoma Biotherapeutics, Sangamo Therapeutics (SGMO), TRex Bio, Mozart Therapeutics, GentiBio, Kyverna Therapeutics (KYTX), Cellenkos, AZ Therapies, and Quell Therapeutics.
• The document states that, to the company's knowledge, there exists no other Treg-derived exosome competitor.
• However, there exists other cell derived exosome competitors including: Evox Therapeutics, Capricor Therapeutics (CAPR), and Exopharm, and Rion.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings.
• Employees: Job security dependent on successful product development and funding.
• Patients: Potential access to new therapies for neurodegenerative and autoimmune diseases.
• Collaborators: Opportunities for partnerships and licensing agreements.
• Creditors: Risk associated with the company's ability to repay debt.

Next Steps

• Complete required nonclinical studies and submit data to support IND for COYA 302 in ALS in the second quarter of 2025.
• Initiate Phase 2 clinical trial in ALS upon FDA approval of the IND.
• Evaluate results of investigator-initiated study of LD IL-2 in FTD patients in the second half of 2025.
• Conduct studies in animal models of PD in 2025 and evaluate making an IND filing for COYA 302 for the treatment of patients with PD.
• Explore partnerships with other pharmaceutical and biotechnology companies for combination therapies with COYA 301.
• Continue ongoing strategic discussions to advance COYA 303 through IND-enabling studies and into the clinic.

Key Dates